Literature DB >> 2387997

Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.

M Tremblay1, M A Wainberg.   

Abstract

Titers of neutralizing antibodies to different strains of human immunodeficiency virus type 1 (HIV-1), including five isolates sequentially obtained from one infected subject, were determined using sequential serum samples obtained from that individual. Neutralizing antibodies were detected against the HIV-IIIB laboratory strain of HIV-1 and against a clinical isolate from another HIV-1-infected individual. Sera from the subject under investigation possessed differential ability to enact viral neutralization, depending on which homotypic clinical isolate was used. In general, it appeared that effective neutralization capacity was present in serum against homotypic viral isolates of HIV-1 only if these isolates were obtained at or before serum collection. These data suggest that variants of HIV-1 in infected individuals may not be effectively neutralized by antibodies that have been generated in these same people against previously dominant viral strains.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2387997     DOI: 10.1093/infdis/162.3.735

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1.

Authors:  Gülsen Ozkaya Sahin; Birgitta Holmgren; Zacarias da Silva; Jens Nielsen; Salma Nowroozalizadeh; Joakim Esbjörnsson; Fredrik Månsson; Sören Andersson; Hans Norrgren; Peter Aaby; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Public versus personal serotypes of a viral quasispecies.

Authors:  Lukas Hunziker; Adrian Ciurea; Mike Recher; Hans Hengartner; Rolf M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-02       Impact factor: 11.205

3.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  HIV-1 infection of in vitro cultured human monocytes: early events and influence of anti HIV-1 antibodies.

Authors:  M Arendrup; S Olofsson; J O Nielsen; J E Hansen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Authors:  Nagadenahalli B Siddappa; Jennifer D Watkins; Klemens J Wassermann; Ruijiang Song; Wendy Wang; Victor G Kramer; Samir Lakhashe; Michael Santosuosso; Mark C Poznansky; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Robert A Rasmussen; Ruth M Ruprecht
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

7.  Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment.

Authors:  Xueling Wu; Tongqing Zhou; Sijy O'Dell; Richard T Wyatt; Peter D Kwong; John R Mascola
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

8.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

9.  Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; S Kliks; P F Wright
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

10.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.